MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 124 filers reported holding MERSANA THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,485 | -61.4% | 5,106 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $16,799 | +5.2% | 5,106 | +31.5% | 0.00% | 0.0% |
| Q1 2023 | $15,963 | -58.1% | 3,884 | -40.3% | 0.00% | -50.0% |
| Q4 2022 | $38,137 | +18.6% | 6,508 | +36.8% | 0.00% | 0.0% |
| Q3 2022 | $32,164 | +46.3% | 4,758 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $21,982 | +15.8% | 4,758 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $18,984 | -67.9% | 4,758 | -50.0% | 0.00% | 0.0% |
| Q4 2021 | $59,227 | -58.0% | 9,522 | -36.3% | 0.00% | -50.0% |
| Q3 2021 | $140,997 | -47.5% | 14,952 | -24.4% | 0.00% | -50.0% |
| Q2 2021 | $268,504 | +13.6% | 19,772 | +35.4% | 0.00% | 0.0% |
| Q1 2021 | $236,309 | -43.9% | 14,605 | -7.8% | 0.00% | -33.3% |
| Q4 2020 | $421,343 | +46.1% | 15,834 | +2.2% | 0.01% | +20.0% |
| Q3 2020 | $288,349 | -14.1% | 15,486 | +7.9% | 0.01% | -16.7% |
| Q2 2020 | $335,767 | +1009.5% | 14,349 | +176.4% | 0.01% | +500.0% |
| Q1 2020 | $30,264 | – | 5,191 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
| Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
| Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
| Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
| Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
| Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
| Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
| DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |